Regression of Sweet's syndrome associated with Crohn's disease after anti-Tumour Necrosis Factor therapy
Rahier, J.F.; Lion, L.; Dewit, O.; Lambert, M.
Acta Gastro-Enterologica Belgica 68(3): 376-379
2005
ISSN/ISBN: 1784-3227 PMID: 16268426 Document Number: 591794
The association of inflammatory bowel disease and acute febrile neutrophilic dermatitis (Sweet's syndrome) has infrequently been reported in the literature. We describe the case of a 41-year-old Caucasian woman with ileo- anal Crohn's disease who presented simultaneously an erythema nodosum and a Sweet's syndrome. A dramatic regression of the cutaneous lesions was observed after infliximab treatment, indicating that this therapy might be useful for both Crohn's disease and Sweet's syndrome.
Document emailed within 1 workday
Related Documents
Sobolewska-Włodarczyk, A.; Zielińska, A.; Siwiński, P.ł; Jędraszczyk, E.; Stec-Michalska, K.; Włodarczyk, M.; Wiśniewska-Jarosińska, M. 2017: The incidence rate of surgical interventions in patients with Crohn's disease treated with anti-tumour necrosis factor biologics Folia Medica Cracoviensia 57(2): 95-104Ip, K.; Hartley, L.; Solanki, K.; White, D. 2015: Retention on anti-tumour necrosis factor therapy: the Waikato experience New Zealand Medical Journal 128(1415): 34-40
Browne, W.L.; Wilson, W.R.; Baguley, B.C.; Ching, L.M. 1998: Suppression of serum tumour necrosis factor-alpha by thalidomide does not lead to reversal of tumour vascular collapse and anti-tumour activity of 5,6-dimethylxanthenone-4-acetic acid Anticancer Research 18(6a): 4409-4413
Jin, D.; Tie, N.; Liu, J.; Zhao, L.; Hao, D.; Zhao, Y. 2015: Investigation of the risk of hepatitis B virus reactivation in arthritis patients undergoing anti-tumour necrosis factor alpha therapy Zhonghua Nei Ke Za Zhi 54(4): 313-316
Sundrarjun, T.; Komindr, S.; Archararit, N.; Dahlan, W.; Puchaiwatananon, O.; Angthararak, S.; Udomsuppayakul, U.; Chuncharunee, S. 2004: Effects of n-3 fatty acids on serum interleukin-6, tumour necrosis factor-alpha and soluble tumour necrosis factor receptor p55 in active rheumatoid arthritis Journal of International Medical Research 32(5): 443-454
De Filippis, L.; Caliri, A.; Anghelone, S.; Scibilia, G.; Lo Gullo, R.; Bagnato, G. 2006: Improving outcomes in tumour necrosis factor a treatment: comparison of the efficacy of the tumour necrosis factor a blocking agents etanercept and infliximab in patients with active rheumatoid arthritis Panminerva Medica 48(2): 129-135
Rémy, A.; Avouac, J.; Gossec, L.; Combe, B. 2011: Clinical relevance of switching to a second tumour necrosis factor-alpha inhibitor after discontinuation of a first tumour necrosis factor-alpha inhibitor in rheumatoid arthritis: a systematic literature review and meta-analysis Clinical and Experimental Rheumatology 29(1): 96-103
Juhl, P.; Thudium, C.S.; Gudmann, N.S.; Karsdal, M.A.; Bay-Jensen, A.-C.; Siebuhr, A.S. 2018: IL-6 receptor inhibition modulates type IIi collagen and C-reactive protein degradation in rheumatoid arthritis patients with an inadequate response to anti-tumour necrosis factor therapy: analysis of connective tissue turnover in the tocilizumab RADIATE study Clinical and Experimental Rheumatology 36(4): 568-574
Nieto González, J.C.; Monteagudo Saez, I.; López-Longo, F.J.; Serrano, B.én.; Mata Martínez, C.; Carreño Pérez, L. 2013: Idiopathic recurrent pericarditis treated successfully with tumour necrosis factor alpha blocking agents (anti-TNF-α) Clinical and Experimental Rheumatology 31(5): 776-778
Ganesan, S.; Travis, S.P.L.; Ahmad, T.; Jazrawi, R. 2002: Therapeutic inhibitors of tumor necrosis factor in Crohn's disease Current Opinion in Investigational Drugs 3(9): 1301-1306
Atzeni, F.; Sarzi-Puttini, P.; Sebastiani, M.; Panetta, V.; Salaffi, F.; Iannone, F.; Carletto, A.; Foti, R.; Gremese, E.; Govoni, M.; Marchesoni, A.; Favalli, E.; Gorla, R.; Ramonda, R.; Ferraccioli, G.; Lapadula, G. 2019: Rate of serious infections in spondyloarthropathy patients treated with anti-tumour necrosis factor drugs: a survey from the Italian registry GISEA Clinical and Experimental Rheumatology 37(4): 649-655
Radhakrishnan, V.V.; Sumi, M.G.; Reuben, S.; Mathai, A.; Nair, M.D. 2003: Circulating tumour necrosis factor alpha and soluble TNF receptors in patients with Guillain-Barre syndrome Indian Journal of Medical Research 117: 216-220
Lucherini, O.M.; Vitale, A.; Obici, L.; Sota, J.; Frediani, B.; Merlini, G.; Rigante, D.; Cantarini, L. 2019: Differential serum levels of interleukin-37 in patients with tumour necrosis factor receptor-associated periodic syndrome (TRAPS) Clinical and Experimental Rheumatology 37 Suppl 121(6): 159-160
Cantarini, L.; Lucherini, O.M.; Galeazzi, M.; Fanti, F.; Simonini, G.; Baldari, C.T.; Laghi Pasini, F.; De Martino, M.; Cimaz, R. 2009: Tumour necrosis factor receptor-associated periodic syndrome caused by a rare mutation in the TNFRSF1A gene, and with excellent response to etanercept treatment Clinical and Experimental Rheumatology 27(5): 890-891
Garcia-Porrua, C.; Gonzalez-Gay, M.A.; Quevedo, V. 2006: Should anti-tumor necrosis factor-alpha be the first therapy for rheumatoid vasculitis? Journal of Rheumatology 33(2): 433; Author Reply 433-4
Belaiche, J.; Louis, E. 2000: Treatment of Crohn disease in adults with tumor necrosis factor-alpha (TNF-alpha) antibodies Revue Medicale de Liege 55(9): 827-832
Shahramian, I.; Noori, N.M.; Hashemi, M.; Sharafi, E.; Baghbanian, A. 2013: A study of serum levels of leptin, ghrelin and tumour necrosis factor-alpha in child patients with cyanotic and acyanotic, congenital heart disease JPMA. Journal of the Pakistan Medical Association 63(11): 1332-1337
Ringrose, J.S.; Sanche, S.E.; Taylor-Gjevre, R.M. 2011: Detecting latent tuberculosis infection during anti-tumor necrosis factor therapy Clinical and Experimental Rheumatology 29(5): 790-794
Feldmann, M.; Brennan, F.; Paleolog, E.; Taylor, P.; Maini, R.N. 1997: Anti-tumor necrosis factor alpha therapy of rheumatoid arthritis. Mechanism of action European Cytokine Network 8(3): 297-300
Inanir, A.; Ozoran, K.; Tutkak, H.; Mermerci, B. 2004: The effects of calcitriol therapy on serum interleukin-1, interleukin-6 and tumour necrosis factor-alpha concentrations in post-menopausal patients with osteoporosis Journal of International Medical Research 32(6): 570-582